PT1427420E - Utilizacao de uma combinacao compreendendo 4- piridilmetilftalazinas para o tratamento do cancro - Google Patents

Utilizacao de uma combinacao compreendendo 4- piridilmetilftalazinas para o tratamento do cancro

Info

Publication number
PT1427420E
PT1427420E PT02779338T PT02779338T PT1427420E PT 1427420 E PT1427420 E PT 1427420E PT 02779338 T PT02779338 T PT 02779338T PT 02779338 T PT02779338 T PT 02779338T PT 1427420 E PT1427420 E PT 1427420E
Authority
PT
Portugal
Prior art keywords
cancer
pyridylmethyltalazines
treatment
combination understanding
understanding
Prior art date
Application number
PT02779338T
Other languages
English (en)
Portuguese (pt)
Inventor
Dugan Margaret Han
Wood Jeanette Marjorie
Original Assignee
Novartis Ag
Novartis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag, Novartis Pharma Gmbh filed Critical Novartis Ag
Publication of PT1427420E publication Critical patent/PT1427420E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PT02779338T 2001-09-12 2002-09-11 Utilizacao de uma combinacao compreendendo 4- piridilmetilftalazinas para o tratamento do cancro PT1427420E (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US31869401P 2001-09-12 2001-09-12
US33102501P 2001-09-12 2001-09-12
US32204401P 2001-09-14 2001-09-14
US38816302P 2002-06-12 2002-06-12

Publications (1)

Publication Number Publication Date
PT1427420E true PT1427420E (pt) 2006-10-31

Family

ID=27502161

Family Applications (1)

Application Number Title Priority Date Filing Date
PT02779338T PT1427420E (pt) 2001-09-12 2002-09-11 Utilizacao de uma combinacao compreendendo 4- piridilmetilftalazinas para o tratamento do cancro

Country Status (22)

Country Link
US (2) US20040258770A1 (enExample)
EP (1) EP1427420B1 (enExample)
JP (1) JP2005502690A (enExample)
KR (1) KR20040029172A (enExample)
CN (1) CN1330308C (enExample)
AT (2) ATE329597T1 (enExample)
AU (2) AU2002342678B2 (enExample)
BR (1) BR0212446A (enExample)
CA (1) CA2457848A1 (enExample)
CO (1) CO5560545A2 (enExample)
CY (1) CY1105189T1 (enExample)
DE (2) DE60231068D1 (enExample)
DK (1) DK1427420T3 (enExample)
ES (2) ES2266590T3 (enExample)
HR (1) HRP20040241A2 (enExample)
IL (1) IL160382A0 (enExample)
NO (1) NO327358B1 (enExample)
NZ (1) NZ531484A (enExample)
PL (1) PL367349A1 (enExample)
PT (1) PT1427420E (enExample)
RS (1) RS16804A (enExample)
WO (1) WO2003022282A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0223341D0 (en) * 2002-10-08 2002-11-13 Groningen Acad Ziekenhuis Organic compounds
WO2004058234A2 (en) * 2002-12-27 2004-07-15 Schering Aktiengesellschaft Pharmaceutical combinations of phthalazine vegf inhibitors and benzamide hdac inhibitors
EP1631278A4 (en) * 2003-05-20 2006-09-20 Aronex Pharmaceuticals Inc COMBINED CHEMOTHERAPY COMPRISING CAPECITABINE AND A COMPLEX BASED ON LIPOSOMIC PLATINUM
BRPI0414698A (pt) * 2003-09-23 2006-11-28 Novartis Ag combinação de um inibidor receptor de vegf com um agente quimioterapêutico
GB0610925D0 (en) * 2006-06-02 2006-07-12 Novartis Ag Use of vascular endothelial growth factor receptor inhibitors for the treatment of cancer
KR101037292B1 (ko) * 2010-09-03 2011-05-27 (주)슈추어 신발 장식구

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2173493C (en) * 1994-08-09 2008-03-25 Nobuhisa Watanabe Fused pyridazine compounds
AU719327B2 (en) * 1996-03-05 2000-05-04 Astrazeneca Ab 4-anilinoquinazoline derivatives
US6096904A (en) * 1996-12-03 2000-08-01 The Trustees Of The University Of Pennsylvania Synthetic techniques and intermediates for polyhydroxy, dienyl lactone derivatives
CO4950519A1 (es) * 1997-02-13 2000-09-01 Novartis Ag Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion

Also Published As

Publication number Publication date
AU2002342678B2 (en) 2006-08-24
IL160382A0 (en) 2004-07-25
DE60212415T2 (de) 2006-11-23
ES2266590T3 (es) 2007-03-01
EP1427420A1 (en) 2004-06-16
EP1427420B1 (en) 2006-06-14
DE60212415D1 (de) 2006-07-27
RS16804A (sr) 2007-02-05
NZ531484A (en) 2007-02-23
JP2005502690A (ja) 2005-01-27
ES2320922T3 (es) 2009-05-29
CN1553803A (zh) 2004-12-08
BR0212446A (pt) 2004-08-17
US20040258770A1 (en) 2004-12-23
CY1105189T1 (el) 2010-03-03
CN1330308C (zh) 2007-08-08
PL367349A1 (en) 2005-02-21
KR20040029172A (ko) 2004-04-03
DE60231068D1 (de) 2009-03-19
AU2006203428B2 (en) 2009-06-04
CA2457848A1 (en) 2003-03-20
NO20040973L (no) 2004-06-03
NO327358B1 (no) 2009-06-15
ATE421880T1 (de) 2009-02-15
ATE329597T1 (de) 2006-07-15
DK1427420T3 (da) 2006-10-02
WO2003022282A1 (en) 2003-03-20
HRP20040241A2 (en) 2005-04-30
AU2006203428A1 (en) 2006-08-31
CO5560545A2 (es) 2005-09-30
US20090196871A1 (en) 2009-08-06

Similar Documents

Publication Publication Date Title
NO20062885L (no) Terapeufiske anti-IGFR1-antistoffkombinasjoner
EA201000016A1 (ru) Способы и композиции для лечения рака, опухолей и нарушений, связанных с опухолями
PL415000A1 (pl) Zastosowanie 40-O-(2-hydroksyetylo)-rapamycyny do wytwarzania leku do leczenia litych guzów ośrodkowego układu nerwowego
NO20091661L (no) Anvendelse av pegylert IL-10 for a behandle kreft
EA200100111A1 (ru) Ингибиторы фарнезилпротеинтрансферазы, обладающие in vivo радиосенсибилизирующими свойствами
EA201890957A1 (ru) Комбинированная терапия для лечения злокачественных опухолей
BRPI0416268A (pt) composições de delta-9-thc e métodos para o tratamento de sintomas associados à esclerose múltipla
NO20040516L (no) Kombinasjonsterapi for behandling av kreft.
WO2004009609A3 (en) Nucleoside compounds and their use for treating cancer and diseases associated with somatic mutations
PT1427420E (pt) Utilizacao de uma combinacao compreendendo 4- piridilmetilftalazinas para o tratamento do cancro
ECSP045408A (es) Composición farmacéutica que comprende arsenito para el tratamiento de malignidad
MXPA04002407A (es) Uso de 4-piridilmeetil-ftalazinas para el tratamiento de cancer.
ATE252896T1 (de) Endokrintherapie für brustkrebs: kombinierte behandlung mit tamoxifen und alkyl-pcdfs
BRPI0417371A (pt) enoxaparina para o tratamento de cáncer
TR200302193T4 (tr) Kombinasyon kemoterapisi.
ECSP044991A (es) Uso de 4-piridilmetil-ftalazinas para el tratamiento de cancer
MX2022006278A (es) Proteinas de salmon uk 114 para uso en el tratamiento, diagnostico y prevencion de tumores malignos.
BRPI0513350A (pt) uso de um agente de quelação de ìon metálico, e, método para o tratamento ou profilaxia de um tumor canceroso mediado por bactérias
ZA200408071B (en) Combination therapy for the treatment of cancer.
MX9701832A (es) Nuevos profarmacos para la terapia de tumores y enfermedades inflamatorias.
TW200626150A (en) Use of Epothilones in the treatment of bone metastasis
UA49216A (uk) Засіб для лікування ускладнень після видалення злоякісних новоутворень шкіри
UA67528A (en) Method for surgical treatment of thyroid cancer
WO2005046607A3 (en) Combinations for the treatment of proliferative diseases
EA200600987A1 (ru) Применение сирамезина в лечении злокачественных опухолей